Literature DB >> 30416782

Serum decorin is a potential prognostic biomarker in patients with acute exacerbation of idiopathic pulmonary fibrosis.

Takefumi Nikaido1, Yoshinori Tanino1, Xintao Wang1, Yuki Sato1, Ryuichi Togawa1, Masami Kikuchi1, Kenichi Misa1, Kazue Saito1, Naoko Fukuhara1, Takaya Kawamata1, Mami Rikimaru1, Takashi Umeda1, Julia Morimoto1, Tatsuhiko Koizumi1, Yasuhito Suzuki1, Kenichiro Hirai1, Manabu Uematsu1, Hiroyuki Minemura1, Atsuro Fukuhara1, Suguru Sato1, Junpei Saito1, Hiroshi Yokouchi1, Kenya Kanazawa1, Yoko Shibata1.   

Abstract

BACKGROUND: Decorin is a small leucine-rich repeat proteoglycan that plays a critical role in collagen fibrillogenesis, and regulates inflammation, wound healing and angiogenesis. In idiopathic pulmonary fibrosis (IPF), decorin is expressed in fibrotic lesions; furthermore, intratracheal gene transfer of decorin has been demonstrated to inhibit bleomycin-induced pulmonary fibrosis. Although these results suggest the critical role of decorin in pulmonary fibrosis, the role of decorin in the acute exacerbation of idiopathic interstitial pneumonia (AE-IIP) has not been clarified in detail. Thus, the goal of this study was to determine the role of decorin in AE-IIP.
METHODS: We retrospectively analyzed AE-IIP patients who had been admitted to our hospital. First, serum decorin levels were compared among patients with AE-IIP, patients with stable idiopathic interstitial pneumonia (SD-IIP), and healthy subjects. Next, the relationship between serum decorin levels and clinical parameters was analyzed in AE-IIP patients. Finally, the association between serum decorin levels and prognosis was evaluated in AE-IIP patients. IIP was divided into IPF and non-IPF, according to the published guidelines.
RESULTS: The serum decorin levels of AE-IIP patients were significantly lower than those of both healthy subjects and SD-IIP patients. Serum decorin levels were not related with the clinical parameters and prognosis, when all IIP patients were analyzed. In IPF patients, serum decorin levels had a significant correlation with oxygenation, and IPF patients with low serum decorin levels had a significantly higher survival rate than those with high serum decorin levels.
CONCLUSIONS: Serum decorin levels are a potential prognostic biomarker in AE-IPF.

Entities:  

Keywords:  Decorin; acute exacerbation (AE); biomarker; idiopathic pulmonary fibrosis (IPF); prognosis

Year:  2018        PMID: 30416782      PMCID: PMC6196213          DOI: 10.21037/jtd.2018.08.60

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  43 in total

1.  Serum Syndecan-4 as a Possible Biomarker in Patients With Acute Pneumonia.

Authors:  Takefumi Nikaido; Yoshinori Tanino; Xintao Wang; Suguru Sato; Kenichi Misa; Naoko Fukuhara; Yuki Sato; Atsuro Fukuhara; Manabu Uematsu; Yasuhito Suzuki; Tetsuhito Kojima; Mishie Tanino; Yuichi Endo; Kohsuke Tsuchiya; Ikuo Kawamura; Charles W Frevert; Mitsuru Munakata
Journal:  J Infect Dis       Date:  2015-04-20       Impact factor: 5.226

2.  The role for decorin in delayed-type hypersensitivity.

Authors:  Daniela G Seidler; Negia A Mohamed; Carla Bocian; Anika Stadtmann; Sven Hermann; Klaus Schäfers; Michael Schäfers; Renato V Iozzo; Alexander Zarbock; Martin Götte
Journal:  J Immunol       Date:  2011-10-31       Impact factor: 5.422

3.  Proteoglycan deposition in pulmonary fibrosis.

Authors:  E S Bensadoun; A K Burke; J C Hogg; C R Roberts
Journal:  Am J Respir Crit Care Med       Date:  1996-12       Impact factor: 21.405

4.  Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats.

Authors:  G Westergren-Thorsson; J Hernnäs; B Särnstrand; A Oldberg; D Heinegård; A Malmström
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

5.  Intratracheal gene transfer of decorin reduces subpleural fibroproliferation induced by bleomycin.

Authors:  Minoru Shimizukawa; Masahito Ebina; Ko Narumi; Toshiaki Kikuchi; Hiroshi Munakata; Toshihiro Nukiwa
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-03       Impact factor: 5.464

6.  Transcriptional regulation of decorin gene expression. Induction by quiescence and repression by tumor necrosis factor-alpha.

Authors:  A Mauviel; M Santra; Y Q Chen; J Uitto; R V Iozzo
Journal:  J Biol Chem       Date:  1995-05-12       Impact factor: 5.157

7.  MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis.

Authors:  Ivan O Rosas; Thomas J Richards; Kazuhisa Konishi; Yingze Zhang; Kevin Gibson; Anna E Lokshin; Kathleen O Lindell; Jose Cisneros; Sandra D Macdonald; Annie Pardo; Frank Sciurba; James Dauber; Moises Selman; Bernadette R Gochuico; Naftali Kaminski
Journal:  PLoS Med       Date:  2008-04-29       Impact factor: 11.069

8.  Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.

Authors:  William M Reichmann; Yanni F Yu; Dendy Macaulay; Eric Q Wu; Steven D Nathan
Journal:  BMC Pulm Med       Date:  2015-12-29       Impact factor: 3.317

9.  Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.

Authors:  Harold R Collard; Eric Yow; Luca Richeldi; Kevin J Anstrom; Craig Glazer
Journal:  Respir Res       Date:  2013-07-13

10.  Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases.

Authors:  Takafumi Suda; Yusuke Kaida; Yutaro Nakamura; Noriyuki Enomoto; Tomoyuki Fujisawa; Shiro Imokawa; Hideo Hashizume; Tateaki Naito; Dai Hashimoto; Yasuo Takehara; Naoki Inui; Hirotoshi Nakamura; Thomas V Colby; Kingo Chida
Journal:  Respir Med       Date:  2009-02-01       Impact factor: 3.415

View more
  8 in total

1.  Acute exacerbation of idiopathic pulmonary fibrosis: who to treat, how to treat.

Authors:  Tejaswini Kulkarni; Steven R Duncan
Journal:  Curr Pulmonol Rep       Date:  2019-11-26

Review 2.  Leveraging 3D Model Systems to Understand Viral Interactions with the Respiratory Mucosa.

Authors:  Ethan Iverson; Logan Kaler; Eva L Agostino; Daniel Song; Gregg A Duncan; Margaret A Scull
Journal:  Viruses       Date:  2020-12-11       Impact factor: 5.048

Review 3.  Granzyme B in Inflammatory Diseases: Apoptosis, Inflammation, Extracellular Matrix Remodeling, Epithelial-to-Mesenchymal Transition and Fibrosis.

Authors:  Francesca Velotti; Ilaria Barchetta; Flavia Agata Cimini; Maria Gisella Cavallo
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

4.  Targeting Asporin in Lung Fibrosis: A New Approach to an Old Concept.

Authors:  Chao He; Yong Zhou
Journal:  Am J Respir Cell Mol Biol       Date:  2022-02       Impact factor: 6.914

Review 5.  Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis.

Authors:  Hongbo Ma; Xuyi Wu; Yi Li; Yong Xia
Journal:  Front Pharmacol       Date:  2022-07-21       Impact factor: 5.988

Review 6.  Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics.

Authors:  Ryan Brown; Sridesh Nath; Alnardo Lora; Ghassan Samaha; Ziyad Elgamal; Ryan Kaiser; Clifford Taggart; Sinéad Weldon; Patrick Geraghty
Journal:  Respir Res       Date:  2020-05-12

7.  Systematic review and meta-analysis of prognostic factors of acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Hiroyuki Kamiya; Ogee Mer Panlaqui
Journal:  BMJ Open       Date:  2020-06-15       Impact factor: 2.692

8.  Distal Lung Microenvironment Triggers Release of Mediators Recognized as Potential Systemic Biomarkers for Idiopathic Pulmonary Fibrosis.

Authors:  Dimitrios Kalafatis; Anna Löfdahl; Per Näsman; Göran Dellgren; Åsa M Wheelock; Linda Elowsson Rendin; Magnus Sköld; Gunilla Westergren-Thorsson
Journal:  Int J Mol Sci       Date:  2021-12-14       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.